NEALS Webinar: Tofersen Update
NEALS Webinar: Tofersen Update Tuesday, May 2, 2023 4:00 PM ET The U.S. Food and Drug Administration (FDA) has granted accelerated approval for tofersen for the treatment of individuals with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Join Dr. Timothy Miller for a webinar update following the FDA’s recent announcement moderated by NEALS…